Evidence map›Paper›PMID 31913341›Full record

ArticleScientific reports2020

Development of a novel anti-hepatitis B virus agent via Sp1.

Michiyo Hayakawa, Hideaki Umeyama, Mitsuo Iwadate, Y-H Taguchi, Yoshihiko Yano, Takashi Honda, Saori Itami-Matsumoto, Ritsuzo Kozuka, Masaru Enomoto, Akihiro Tamori and 2 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Kaempferol inhibits hepatitis B virus replicationFrontiers in cellular and infection microbiology · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Michiyo HayakawaDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, 545-8585, Japan.
Hideaki UmeyamaDepartment of Biological Sciences, Chuo University, Tokyo, 112-8551, Japan.
Mitsuo IwadateDepartment of Biological Sciences, Chuo University, Tokyo, 112-8551, Japan.
Y-H TaguchiDepartment of Physics, Chuo University, Tokyo, 112-8551, Japan.ORCID http://orcid.org/0000-0003-0867-8986
Yoshihiko YanoDivision of Gastroenterology, Department of Internal of Medicine, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.
Takashi HondaDivision of Gastroenterology, Department of Internal Medicine, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Saori Itami-MatsumotoDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, 545-8585, Japan.
Ritsuzo KozukaDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, 545-8585, Japan.
Masaru EnomotoDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, 545-8585, Japan.
Akihiro TamoriDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, 545-8585, Japan.ORCID http://orcid.org/0000-0001-9119-4864
Norifumi KawadaDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, 545-8585, Japan.
Yoshiki MurakamiDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, 545-8585, Japan. yoshikim@tokyo-med.ac.jp.
Osaka City University · JPChuo University · JPKobe University · JPNagoya University · JPTokyo Medical University · JP

Funding

Japan Agency for Medical Research and Development (AMED) JP15fk0310001h0003
6 · The paper itself

Abstract

Nucleos(t)ide analog (NA) therapy has proven effective in treating chronic hepatitis B. However, NAs frequently result in viral relapse after the cessation of therapy. This is because NAs cannot fully eliminate the viral episomal covalently closed circular DNA (cccDNA) in the nucleus. In this study, we identified small molecular compounds that control host factors related to viral replication using in silico screening with simulated annealing based on bioinformatics for protein-ligand flexible docking. Twelve chemical compound candidates for alpha-glucosidase (AG) inhibitors were identified from a library of chemical compounds and used to treat fresh human hepatocytes infected with HBV. They were then monitored for their anti-viral effects. HBV replication was inhibited by one candidate (1-[3-(4-tert-butylcyclohexyl)oxy-2-hydroxypropyl]-2,2,6,6-tetramethylpiperidin-4-ol) in a dose-dependent manner. This compound significantly reduced ccc DNA production, compared to Entecavir (p < 0.05), and had a lower anti-AG effect. Gene expression analysis and structural analysis of this compound showed that its inhibitive effect on HBV was via interaction with Sp1. The nuclear transcription factor Sp1 acts on multiple regions of HBV to suppress HBV replication. Identifying candidates that control nuclear transcription factors facilitate the development of novel therapies. Drugs with a mechanism different from NA are promising for the elimination of HBV.

Indexed as

Drug Developmentalpha-GlucosidasesAntiviral AgentsDNA, CircularDNA, ViralGlycoside Hydrolase InhibitorsHepatitis BHepatitis B virusHepatocytesHigh-Throughput Screening AssaysHumansSp1 Transcription FactorVirus Replicationalpha-GlucosidasesAntiviral AgentsDNA, CircularDNA, ViralGlycoside Hydrolase InhibitorsSP1 protein, humanSp1 Transcription Factor

Identifiers

PMID31913341
PMCPMC6949255
OpenAlexW2999394169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.